abbv-637
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2021 (NCT04721015)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Aspartyl/asparaginyl beta-hydroxylaseBINDING AGENT
ASPH binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06934889 | Phase 1 | Apr 7, 2025 | Memorial Sloan-Kettering Cancer Center |
| NCT04721015 | Phase 1 | Feb 18, 2021 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1